AUS Bio Limited:製品開発パイプライン動向2015

Global Markets Directが発行した調査報告書(GMDHC06935CDB)
◆英語タイトル:AUS Bio Limited - Product Pipeline Review - 2015
◆発行会社(リサーチ会社):Global Markets Direct
◆レポート形式:英語 / PDF
Single UserUSD1,500 ⇒換算¥169,500見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD4,500 ⇒換算¥508,500見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。


AUS Bio Limited – Product Pipeline Review – 2015


Global Markets Direct’s, ‘AUS Bio Limited – Product Pipeline Review – 2015’, provides an overview of the AUS Bio Limited’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AUS Bio Limited’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides brief overview of AUS Bio Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of AUS Bio Limited’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the AUS Bio Limited’s pipeline products

Reasons to buy

- Evaluate AUS Bio Limited’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of AUS Bio Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the AUS Bio Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of AUS Bio Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of AUS Bio Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of AUS Bio Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues


Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
AUS Bio Limited Snapshot 4
AUS Bio Limited Overview 4
Key Information 4
Key Facts 4
AUS Bio Limited – Research and Development Overview 5
Key Therapeutic Areas 5
AUS Bio Limited – Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products – Monotherapy 8
AUS Bio Limited – Pipeline Products Glance 9
AUS Bio Limited – Early Stage Pipeline Products 9
Preclinical Products/Combination Treatment Modalities 9
AUS Bio Limited – Drug Profiles 10
MD-2009 10
Product Description 10
Mechanism of Action 10
R&D Progress 10
MD-920G 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
MD-960 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
MD-990 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
AUS Bio Limited – Pipeline Analysis 14
AUS Bio Limited – Pipeline Products by Target 14
AUS Bio Limited – Pipeline Products by Route of Administration 15
AUS Bio Limited – Pipeline Products by Molecule Type 16
AUS Bio Limited – Pipeline Products by Mechanism of Action 17
AUS Bio Limited – Dormant Projects 18
AUS Bio Limited – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Appendix 20
Methodology 20
Coverage 20
Secondary Research 20
Primary Research 20
Expert Panel Validation 20
Contact Us 20
Disclaimer 21

[List of Tables]
AUS Bio Limited, Key Information 4
AUS Bio Limited, Key Facts 4
AUS Bio Limited - Pipeline by Indication, 2015 6
AUS Bio Limited - Pipeline by Stage of Development, 2015 7
AUS Bio Limited - Monotherapy Products in Pipeline, 2015 8
AUS Bio Limited - Preclinical, 2015 9
AUS Bio Limited - Pipeline by Target, 2015 14
AUS Bio Limited - Pipeline by Route of Administration, 2015 15
AUS Bio Limited - Pipeline by Molecule Type, 2015 16
AUS Bio Limited - Pipeline Products by Mechanism of Action, 2015 17
AUS Bio Limited - Dormant Developmental Projects,2015 18
AUS Bio Limited, Other Locations 19

[List of Figures]
AUS Bio Limited - Pipeline by Top 10 Indication, 2015 6


AUS Bio Limited、製品開発、製薬、医薬品、治験、研究開発、パイプライン


★リサーチレポート[ AUS Bio Limited:製品開発パイプライン動向2015(AUS Bio Limited - Product Pipeline Review - 2015)]についてメールでお問い合わせはこちらでお願いします。